

Akums India licenses patented alopecia treatment from Canada's Triple Hair Group

22 October 2024 | News

Revolutionary topical solution aims to enhance hair loss treatment and boost user compliance



Akums Drugs & Pharmaceuticals has announced a strategic partnership with Triple Hair Group, a Canadian company specialising in the development of innovative treatments for androgenic alopecia, for the exclusive licensing of their patented topical formulation for the Indian market.

This advanced formulation combines three unique medicaments to combat alopecia, a common condition affecting millions in India and worldwide.

The newly licensed topical solution is designed to provide a comprehensive approach to hair care. It works to prevent hair fall, stimulate new hair growth, and enhance hair thickness and density, offering a one-stop solution for those battling hair thinning and baldness.

This cutting-edge formula promises a convenient and effective option for users who prefer topical treatments, with the potential to improve compliance and outcomes for individuals struggling with hair loss.

Sanjeev Jain, Managing Director, Akums shared that "Akums' collaboration with Triple Hair marks a significant step towards expanding our dermatology portfolio and providing innovative and effective solutions for hair care in the Indian market."

Jean-Philippe Gravel, CEO of Triple Hair, said "One of the great advantages of this partnership is that Akums will be directly involved in the regulatory process, including an upcoming Phase III clinical trial in India. We expect to start the process in the coming weeks so that we can commercialize Therapy-07 in India as soon as possible."